Interní Med. 2016; 18(3): 137-141 | DOI: 10.36290/int.2016.032

Hyperuricaemia and gouty arthropathy: diagnosis and treatment

MUDr.Radka Svobodová
Revmatologický ústav Praha

Hyperuricaemia refers to a pathological increase in serum uric acid level. Long-lasting hyperuricaemia can lead to so-called gouty

arthropathy that is manifested by a response of the body to uric acid (sodium urate) crystal deposition in joints as well as soft

tissues. Hyperuricaemia can initially be asymptomatic; later on, it can present as acute gouty arthritis. When during sodium urate

crystal deposition in tissues and articular structures their destruction occurs, this is referred to as chronic arthropathic tophaceous

gout; when there is sodium urate deposition in the kidneys, it is called urate nephropathy. The diagnosis of gout is based on

clinical, laboratory, and radiological presentation and mainly on the demonstration of crystals under a polarised microscope. The

therapeutic target is to suppress ongoing inflammation and reduce pain intensity, maintain serum uric acid concentration below

360 μmol/l, remove sodium urate deposits from tissues, and prevent further gout attacks. For this purpose, non-pharmacological

and pharmacological strategies are used.

Keywords: hyperuricaemia, gouty arthritis, alopurinol, febuxostat

Published: July 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svobodová R. Hyperuricaemia and gouty arthropathy: diagnosis and treatment. Interní Med. 2016;18(3):137-141. doi: 10.36290/int.2016.032.
Download citation

References

  1. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II. Management, Report of a task force of the EULAR Standing Committee for international Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324. Go to original source... Go to PubMed...
  2. Závada J, Pavelka K. Dnavá artritida In: Pavelka K, Vencovský J, Horák P, et al. Revmatologie. Maxdorf 2012; s. 432-446.
  3. Pavelka K. Dna (arthritis urica). In: Pavelka K, Rovenský J, et al. Klinická revmatologie. Galén 2003; s. 347-358.
  4. Němec P. Dna a kardiovaskulární riziko. Acta Medicinae. Reprint 2014; 7.
  5. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-115. Go to original source... Go to PubMed...
  6. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900. Go to original source... Go to PubMed...
  7. Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ; 2012: 344, d8190. Go to original source... Go to PubMed...
  8. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900. Go to original source... Go to PubMed...
  9. Zhang W, Doherty M, Pascual E, et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006; 65(10): 1301-1311. Go to original source...
  10. Gray RG, Tenenbaum J, Gottlieb NL, et al. Local corticosteroid injection treatment in rheumatoid disorders. Semin Arthritis Rheum 1981; 10: 231-254. Go to original source...
  11. Němec P. Febuxostat - nové možnosti v léčbě dny. Farmakoterapie. Reprint. 2012; 8(Supplementum 1).
  12. Pavelka K. Terapie dny. In: Pavelka K et al: Farmakoterapie revmatických onemocnění. Garada Publishing 2005; s. 345-351.
  13. Burns CM, Wortmann RL. Latest evidence on gout management: what the clinician needs to know. Ther Adv Chronic Dis 2012; 3: 271-286. Go to original source... Go to PubMed...
  14. Bomalski JS, Clarck M. Serum uric acid-lowering therapies: where are we fading in management of hyperuricemia and potential role of uricase. Curr Rheum Rep. 2004; 6: 204-207. Go to original source...
  15. Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch. 2008; 75: 2-3. Go to original source...
  16. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461. Go to original source...
  17. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effect of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-1548. Go to original source...
  18. Singh JA, Akhras KS, Shiozawa. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther 2015; 17: 120-132. Go to original source...
  19. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36: 1273-1282. Go to original source... Go to PubMed...
  20. Schumacher HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout. 5 year findings of the FOCUS efficacy and safety study. Rheumatology 2009; 48: 188-194. Go to original source...
  21. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012; 71: 1839-1848. Go to original source...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.